Wednesday 6-18-2014 Myriad Genetics (MYGN) $MYGN opened at 36.72 hitting the high price of 37.01 and a day low of 36.25 with a total volume of 932,583. MYGN had a previous close of 36.76 and has been seeing an average volume of 1,281,205.
Overall Average: 40% Buy
Recent stock forum discussions about MYGN http://investorshangout.com/search?q=MYGN&...mp;yt0=Go!
Research and Markets: Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
Business Wire - Wed Jun 18, 11:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8tqg4/vital_signs) has announced the addition of the "Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue" report to their offering. (full story)
Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
M2 - Wed Jun 18, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dj8ssn/vital_signs) has announced the addition of the "Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue" report to their offering. This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm' and what these deals mean for the industry. Additionally, Illumina's first stab at personalized medicine through a partnership with Amgen is explored. For more information visit http://www.researchandmarkets.com/research/dj...ital_signs About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
Announcements, Stock Splits, Hotel Payments Options, Management Changes, and Stockholders Meeting Schedule - Analyst Notes on MSG, Alaska Air, Expedia, Myriad and Liberty Media
PR Newswire - Wed Jun 18, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding The Madison Square Garden Co. (NASDAQ: MSG), Alaska Air Group, Inc. (NYSE: ALK), Expedia Inc. (NASDAQ: EXPE), Myriad Genetics, Inc. (NASDAQ: MYGN) and Liberty Media Corp. (NASDAQ: LMCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3830-100free. (full story)
Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status
Business Wire - Mon Jun 16, 7:01AM CDT
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court's decision to strike down Myriad's monopoly on genetic information related to a woman's risk of breast cancer. Undeterred by the Supreme Court's action, Myriad has continued to engage in conduct intending to suppress women's options for breast cancer screening, including this latest action. (full story)
3 Stocks Rising on Unusual Volume
at The Street - Mon Jun 16, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility. (full story)
Watch for Myriad Genetics to Potentially Pullback After Gaining 3.40% Yesterday
Comtex SmarTrend(R) - Fri Jun 13, 4:40PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.45 to a high of $35.86. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $35.21 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
SmarTrend Watching for Potential Pullback in Shares of Myriad Genetics After 3.40% Gain
Comtex SmarTrend(R) - Fri Jun 13, 4:40PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.45 to a high of $35.86. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $35.21 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
United States (USA) Molecular Diagnostics Market, Test Volume Forecast & Companies
PR Newswire Europe - Wed Jun 11, 1:28AM CDT
DUBLIN, May 20, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hh5n9w/united_states [http://www.researchandmarkets.com/research/hh5n9w/united_states]) has announced the addition of the "United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies" [http://www.researchandmarkets.com/research/hh5n9w/united_states] report to their offering. (full story)
Crescendo Bioscience to Present Multiple Studies at 2014 EULAR Meeting
GlobeNewswire - Tue Jun 10, 3:05PM CDT
Vectra DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage (full story)
MYRIAD GENETICS
at Investor's Business Daily - Mon Jun 09, 5:39PM CDT
MYRIAD GENETICS (MYGN) CFO James Evans quit but will stay until the genetics firm names a successor. (full story)
Myriad Announces Retirement of James Evans, Chief Financial Officer
GlobeNewswire - Mon Jun 09, 3:05PM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the Company's CFO until a replacement can be found. Myriad will engage a leading executive search firm to conduct a national search and will consider both internal and external candidates for the position. (full story)
MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players
M2 - Fri Jun 06, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfmskz/medipoint) has announced the addition of the "MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players" report to their offering. A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories. The report identifies and analyzes the key companies shaping and driving the Companion Diagnostic market. The report provides insight into the competitive Companion Diagnostic landscape, including new companies entering the market and pipeline products in development. Scope - Investigation of current and future market competition for Companion Diagnostic - Competitor assessment including device approval analysis. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors using Companion Diagnostic in clinical practice. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Competitive Assessment - Techniques in Use by Currently Marketed Products - Immunohistochemistry - Fluorescence In Situ Hybridization - Polymerase Chain Reaction - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 4 Pipeline Products - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 5 Current and Future Players - Trends in Corporate Strategy - Companion Diagnostics Business Models - Company Profiles - Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests - Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies) 6 Appendix Companies Mentioned - Amgen - Arno Therapeutics - AstraZeneca - Bristol-Myers Squibb - Clovis Oncology - Eli Lilly and Company - Genentech (Roche) - Pfizer - Syndax Pharmaceuticals - Abbott Laboratories - Amoy Diagnostics (Amoy Diagnostics) - Biogenex Laboratories - BioM?rieux - Dako (Agilent Technologies) - Illumina - Leica Biosystems - Life Technologies (Thermo Fisher Scientific) - MolecularMD - Myriad Genetics - Qiagen - Roche Diagnostics - Siemens Healthcare - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/mfmskz/medipoint (full story)
3 Nasdaq Stocks Investors Love to Hate
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 04, 5:16PM CDT
Don't look now, but it appears that the technology-heavy Nasdaq Composite is again slowly marching toward a multi-decade high. Just when it looked as if a viable correction in social media and biotechnology stocks would drag down the mighty... (full story)
Myriad Genetics Posts Key myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 2:00PM CDT
Management at Myriad Genetics (MYGN) strongly believes that myPath Melanoma has the potential to significantly improve the standard of patient care for those diagnosed with melanoma. (full story)
Life After Pfizer: AstraZeneca Hopes for Oncology Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 03, 8:00AM CDT
European and U.S. regulators this year are considering approval for AstraZeneca 's Olaparib, a drug designed to treat ovarian cancer patients with a specific mutation to the BRCA gene. Approval could have an impact on a variety of other... (full story)
Myriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
GlobeNewswire - Tue Jun 03, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 35 annual Goldman Sachs Global Healthcare Conference, at 10:40 a.m. Pacific on June 10, 2014, at the Terranea Resort in Rancho Palos Verdes, California. (full story)
Myriad Genetics to Unveil BRACAnalysis, HRD Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 2:30PM CDT
Myriad Genetic's (MYGN) BRAC Analysis CDx detected that, in a trial set of 86 metastatic breast cancer patients, the response rate to platinum based therapies was 54.5% for patients with deleterious mutations. (full story)
Myriad Genetics Announces Participation in Innovative Collaboration to Accelerate Hereditary Cancer Research
GlobeNewswire - Mon Jun 02, 9:45AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically advance the understanding of the risks associated with multiple cancer genes that are being analyzed through next generation sequencing technology. Specifically, the partners will collaborate on the creation of a research study called the Prospective Registry of Multiplex Testing (PROMPT). (full story)
Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 8:25AM CDT
Retrophin (RTRX) was a big mover last session, with shares rising nearly 14% on the day. (full story)
Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 7:44AM CDT
Allergan Inc. (AGN) was a big mover last session as the company saw its shares rise over 5% on the day. (full story)
Overall Average: 40% Buy
Recent stock forum discussions about MYGN http://investorshangout.com/search?q=MYGN&...mp;yt0=Go!
Research and Markets: Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
Business Wire - Wed Jun 18, 11:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8tqg4/vital_signs) has announced the addition of the "Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue" report to their offering. (full story)
Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
M2 - Wed Jun 18, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dj8ssn/vital_signs) has announced the addition of the "Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue" report to their offering. This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm' and what these deals mean for the industry. Additionally, Illumina's first stab at personalized medicine through a partnership with Amgen is explored. For more information visit http://www.researchandmarkets.com/research/dj...ital_signs About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
Announcements, Stock Splits, Hotel Payments Options, Management Changes, and Stockholders Meeting Schedule - Analyst Notes on MSG, Alaska Air, Expedia, Myriad and Liberty Media
PR Newswire - Wed Jun 18, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding The Madison Square Garden Co. (NASDAQ: MSG), Alaska Air Group, Inc. (NYSE: ALK), Expedia Inc. (NASDAQ: EXPE), Myriad Genetics, Inc. (NASDAQ: MYGN) and Liberty Media Corp. (NASDAQ: LMCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3830-100free. (full story)
Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status
Business Wire - Mon Jun 16, 7:01AM CDT
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court's decision to strike down Myriad's monopoly on genetic information related to a woman's risk of breast cancer. Undeterred by the Supreme Court's action, Myriad has continued to engage in conduct intending to suppress women's options for breast cancer screening, including this latest action. (full story)
3 Stocks Rising on Unusual Volume
at The Street - Mon Jun 16, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility. (full story)
Watch for Myriad Genetics to Potentially Pullback After Gaining 3.40% Yesterday
Comtex SmarTrend(R) - Fri Jun 13, 4:40PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.45 to a high of $35.86. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $35.21 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
SmarTrend Watching for Potential Pullback in Shares of Myriad Genetics After 3.40% Gain
Comtex SmarTrend(R) - Fri Jun 13, 4:40PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.45 to a high of $35.86. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $35.21 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
United States (USA) Molecular Diagnostics Market, Test Volume Forecast & Companies
PR Newswire Europe - Wed Jun 11, 1:28AM CDT
DUBLIN, May 20, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hh5n9w/united_states [http://www.researchandmarkets.com/research/hh5n9w/united_states]) has announced the addition of the "United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies" [http://www.researchandmarkets.com/research/hh5n9w/united_states] report to their offering. (full story)
Crescendo Bioscience to Present Multiple Studies at 2014 EULAR Meeting
GlobeNewswire - Tue Jun 10, 3:05PM CDT
Vectra DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage (full story)
MYRIAD GENETICS
at Investor's Business Daily - Mon Jun 09, 5:39PM CDT
MYRIAD GENETICS (MYGN) CFO James Evans quit but will stay until the genetics firm names a successor. (full story)
Myriad Announces Retirement of James Evans, Chief Financial Officer
GlobeNewswire - Mon Jun 09, 3:05PM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the Company's CFO until a replacement can be found. Myriad will engage a leading executive search firm to conduct a national search and will consider both internal and external candidates for the position. (full story)
MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players
M2 - Fri Jun 06, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfmskz/medipoint) has announced the addition of the "MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players" report to their offering. A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories. The report identifies and analyzes the key companies shaping and driving the Companion Diagnostic market. The report provides insight into the competitive Companion Diagnostic landscape, including new companies entering the market and pipeline products in development. Scope - Investigation of current and future market competition for Companion Diagnostic - Competitor assessment including device approval analysis. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors using Companion Diagnostic in clinical practice. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Competitive Assessment - Techniques in Use by Currently Marketed Products - Immunohistochemistry - Fluorescence In Situ Hybridization - Polymerase Chain Reaction - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 4 Pipeline Products - Breast Cancer Companion Diagnostic Tests - Colorectal Cancer Companion Diagnostic Tests - Melanoma Companion Diagnostic Tests - Non-Small Cell Lung Cancer Companion Diagnostic Tests 5 Current and Future Players - Trends in Corporate Strategy - Companion Diagnostics Business Models - Company Profiles - Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests - Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies) 6 Appendix Companies Mentioned - Amgen - Arno Therapeutics - AstraZeneca - Bristol-Myers Squibb - Clovis Oncology - Eli Lilly and Company - Genentech (Roche) - Pfizer - Syndax Pharmaceuticals - Abbott Laboratories - Amoy Diagnostics (Amoy Diagnostics) - Biogenex Laboratories - BioM?rieux - Dako (Agilent Technologies) - Illumina - Leica Biosystems - Life Technologies (Thermo Fisher Scientific) - MolecularMD - Myriad Genetics - Qiagen - Roche Diagnostics - Siemens Healthcare - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/mfmskz/medipoint (full story)
3 Nasdaq Stocks Investors Love to Hate
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 04, 5:16PM CDT
Don't look now, but it appears that the technology-heavy Nasdaq Composite is again slowly marching toward a multi-decade high. Just when it looked as if a viable correction in social media and biotechnology stocks would drag down the mighty... (full story)
Myriad Genetics Posts Key myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 2:00PM CDT
Management at Myriad Genetics (MYGN) strongly believes that myPath Melanoma has the potential to significantly improve the standard of patient care for those diagnosed with melanoma. (full story)
Life After Pfizer: AstraZeneca Hopes for Oncology Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 03, 8:00AM CDT
European and U.S. regulators this year are considering approval for AstraZeneca 's Olaparib, a drug designed to treat ovarian cancer patients with a specific mutation to the BRCA gene. Approval could have an impact on a variety of other... (full story)
Myriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
GlobeNewswire - Tue Jun 03, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 35 annual Goldman Sachs Global Healthcare Conference, at 10:40 a.m. Pacific on June 10, 2014, at the Terranea Resort in Rancho Palos Verdes, California. (full story)
Myriad Genetics to Unveil BRACAnalysis, HRD Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 2:30PM CDT
Myriad Genetic's (MYGN) BRAC Analysis CDx detected that, in a trial set of 86 metastatic breast cancer patients, the response rate to platinum based therapies was 54.5% for patients with deleterious mutations. (full story)
Myriad Genetics Announces Participation in Innovative Collaboration to Accelerate Hereditary Cancer Research
GlobeNewswire - Mon Jun 02, 9:45AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically advance the understanding of the risks associated with multiple cancer genes that are being analyzed through next generation sequencing technology. Specifically, the partners will collaborate on the creation of a research study called the Prospective Registry of Multiplex Testing (PROMPT). (full story)
Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 8:25AM CDT
Retrophin (RTRX) was a big mover last session, with shares rising nearly 14% on the day. (full story)
Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 7:44AM CDT
Allergan Inc. (AGN) was a big mover last session as the company saw its shares rise over 5% on the day. (full story)
